Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in Becton, Dickinson and Company $BDX

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 4,279 shares of the medical instruments supplier’s stock, valued at approximately $673,000.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares in the last quarter. Graybill Wealth Management LTD. lifted its holdings in shares of Becton, Dickinson and Company by 47.3% during the 3rd quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock valued at $5,164,000 after acquiring an additional 8,859 shares in the last quarter. Danske Bank A S acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $34,596,000. Cinctive Capital Management LP boosted its position in Becton, Dickinson and Company by 71.6% during the 3rd quarter. Cinctive Capital Management LP now owns 16,847 shares of the medical instruments supplier’s stock worth $3,153,000 after purchasing an additional 7,028 shares during the period. Finally, Legal & General Group Plc increased its holdings in Becton, Dickinson and Company by 3.9% in the 3rd quarter. Legal & General Group Plc now owns 1,919,404 shares of the medical instruments supplier’s stock valued at $359,255,000 after purchasing an additional 71,676 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Stifel Nicolaus cut their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Bank of America lowered their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Piper Sandler dropped their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Finally, Argus decreased their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $181.00.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,188 shares of company stock worth $765,120 over the last 90 days. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $158.10 on Friday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The firm has a market capitalization of $43.56 billion, a P/E ratio of 40.02, a P/E/G ratio of 11.19 and a beta of 0.21. The company’s fifty day moving average price is $147.98 and its two-hundred day moving average price is $169.33.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same period last year, the firm earned $3.35 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.